Trials / Terminated
TerminatedNCT02592863
Trental for the Treatment of Vertigo/Dizziness/Imbalance
A Double-Blind, Placebo-Controlled, Randomized Trial of Pentoxifylline for Imbalance Secondary to Insufficient Microvascular Perfusion
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- University of Missouri-Columbia · Academic / Other
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
Imbalance, dizziness and vertigo as a result of problems in the inner ear (vestibular dysfunction) are becoming increasingly more prevalent in Americans 40 years of age and older. The symptoms have a severe impact on affected individuals with detrimental effects on work, travel, social and family life. These patients see doctors often with no relief in their symptoms. The most promising help for these patients is to use medication that will increase blood flow to the inner ear. Pentoxifylline (Trental) has been shown to increase microvascular blood flow.
Detailed description
One potential cause of vestibular dysfunction is a decrease in or insufficient blood flow to the inner ear. Studies have shown that when the blood flow is decreased to the inner ear, patients will become dizzy and off balance. This study will use validated instruments to evaluate the effectiveness of Trental in patients that present to our providers with vertigo, dizziness, or imbalance and meet inclusion criteria. They will be blinded and randomized to treatment or placebo, which they will take for \~12 weeks. Patients will completed validated surveys 3 times (beginning, middle and end of study) as well as account for the number of times they have fallen and if they have missed any work due to their symptoms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pentoxifylline | Patients will take Trental (Pentoxifylline) 3 times per day for 12 weeks |
| DRUG | Placebo | Patients will take placebo 3 times per day for 12 weeks |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2020-12-31
- Completion
- 2021-04-12
- First posted
- 2015-10-30
- Last updated
- 2024-10-15
- Results posted
- 2024-10-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02592863. Inclusion in this directory is not an endorsement.